• Incyte disclosed Phase 1/2 multidose data for VGA039 (latarcibart) in von Willebrand disease, supporting ongoing pivotal Phase 3 development.
• Across 16 patients, median annualized bleeding rate fell 81% with once-monthly subcutaneous dosing; reductions were reported across all VWD types.
• Patients switching from VWF-containing IV prophylaxis saw 75%-100% bleed reductions, suggesting potential improvement versus current prophylactic practice.
• Safety profile appeared favorable; three treatment-related adverse events were reported, including Grade 2 headaches and a Grade 1 injection-site reaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713735007) on July 13, 2026, and is solely responsible for the information contained therein.